4//SEC Filing
Lismore Damian T. 4
Accession 0001572426-17-000032
CIK 0001618561other
Filed
Aug 1, 8:00 PM ET
Accepted
Aug 2, 9:36 PM ET
Size
16.3 KB
Accession
0001572426-17-000032
Insider Transaction Report
Form 4
Lismore Damian T.
Chief Financial Officer
Transactions
- Disposition to Issuer
Ordinary Shares
2017-07-31$6.72/sh−67,750$455,280→ 0 total - Disposition to Issuer
Ordinary Shares
2017-07-31$6.72/sh−21,239$142,726→ 0 total(indirect: By Spouse) - Disposition to Issuer
Ordinary Shares
2017-07-31$6.72/sh−18,724$125,825→ 0 total(indirect: Glenariff Superannuation Pty Ltd <Glenariff Super Fund A/C>) - Disposition to Issuer
Option to Purchase Shares
2017-07-31−100,000→ 0 totalExercise: $15.00Exp: 2020-05-18→ Ordinary Shares (100,000 underlying) - Disposition to Issuer
Restricted Share Units
2017-07-31$6.59/sh−27,500$181,363→ 0 totalExercise: $0.13Exp: 2020-07-01→ Ordinary Shares (27,500 underlying) - Disposition to Issuer
Restricted Share Units
2017-07-31$6.59/sh−48,750$321,506→ 0 totalExercise: $0.13Exp: 2021-07-01→ Ordinary Shares (48,750 underlying)
Footnotes (5)
- [F1]Disposed of pursuant to a transaction agreement between the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired the Issuer.
- [F2]The reporting person and his spouse share voting and dispositive power with respect to these reported securities.
- [F3]This restricted share unit, which would have vested and become convertible as to 13,750 shares on each of 7/1/18 and 7/1/19, in each case subject to payment of the nominal value per share of $0.125 to the Issuer within 30 days of vesting, was cancelled in the Acquisition in exchange for a cash payment equal to $181,362.50. This amount represents the difference between such nominal value per share and the $6.72 consideration per share payable in connection with in the Acquisition, multiplied by the number of shares issuable on conversion of the restricted share unit.
- [F4]This restricted share unit, which would have vested and become convertible as to 16,250 shares on each of 7/1/18, 7/1/19 and 7/1/20, in each case subject to payment of the nominal value per share of $0.125 to the Issuer within 30 days of vesting, was cancelled in the Acquisition in exchange for a cash payment equal to $321,506.25. This amount represents the difference between such nominal value per share and the $6.72 consideration per share payable in connection with in the Acquisition, multiplied by the number of shares issuable on conversion of the restricted share unit.
- [F5]This option, which was vested as to 70,000 shares and would have vested as to 5,000 shares on each of 9/30/17, 12/31/17, 3/31/18, 6/30/18, 9/30/18 and 12/31/18, was cancelled in the Acquisition in exchange for no cash payment because the $15.00 exercise price per share exceeded the $6.72 consideration per share payable in connection with in the Acquisition.
Documents
Issuer
Nexvet Biopharma plc
CIK 0001618561
Entity typeother
Related Parties
1- filerCIK 0001560864
Filing Metadata
- Form type
- 4
- Filed
- Aug 1, 8:00 PM ET
- Accepted
- Aug 2, 9:36 PM ET
- Size
- 16.3 KB